In the AML TCGA dataset, patients with TP53 mutations exhibited elevated PD-L1 expression relative to those with unmutated TP53 [32], which may lead to the development of ICIs for TP53-mutated AML in the future. Here, TP53 is linked to acute myeloid leukemia.